8-K: MAIA Biotech Initiates Phase 3 NSCLC Trial, Insiders Buy Shares

MAIA Biotechnology has initiated its pivotal Phase 3 THIO-104 trial for ateganosine in advanced non-small cell lung cancer, with leadership demonstrating confidence through significant insider share purchases.

Summary

• MAIA Biotechnology, Inc. has initiated its pivotal Phase 3 THIO-104 clinical trial for ateganosine as a third-line treatment for advanced non-small cell lung cancer (NSCLC).
• The first patient has been dosed in the multicenter, open-label trial, which aims to enroll up to 300 patients and compare ateganosine sequenced with a checkpoint inhibitor (CPI) against investigator's choice of chemotherapy.
• MAIA's leadership, including CEO Dr. Vlad Vitoc, acquired approximately 182,445 shares between November 21 and 28, 2025, signaling strong confidence in the company's strategy and ateganosine platform.
• Directors and Officers collectively hold 4,480,120 shares, representing 12.95% of the company.
• Ateganosine has received Fast Track designation from the U.S. FDA for NSCLC treatment.
• Phase 2 trial data (THIO-101) showed a median overall survival of 17.8 months, significantly higher than the approximately six months observed with chemotherapy, and a progression-free survival (PFS) of 5.6 months, more than double the standard of care PFS of 2.5 months.
• Ateganosine is described as a first-in-class telomere-targeting agent with a dual mechanism of action, disrupting telomeric structure and activating both innate and adaptive immune responses.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive news, including the initiation of a pivotal Phase 3 trial, strong insider confidence through share purchases, and highly encouraging Phase 2 clinical data that significantly outperforms standard of care. The unique mechanism of action and FDA Fast Track designation further bolster the positive outlook, indicating strong progress and potential for future success.

Positives

• Initiation of a pivotal Phase 3 trial for ateganosine, a critical step towards regulatory approval and commercialization.
• Strong insider confidence demonstrated by leadership's purchase of approximately 182,445 shares and a total insider holding of 12.95% of the company.
• Encouraging Phase 2 clinical data for ateganosine, showing a median overall survival of 17.8 months compared to approximately six months for chemotherapy, and a progression-free survival (PFS) of 5.6 months versus 2.5 months for standard of care.
• U.S. FDA Fast Track designation for ateganosine in NSCLC, potentially accelerating the development and review process.
• Ateganosine is a potential first-in-class telomere-targeting agent with a unique dual mechanism of action, differentiating it from existing therapies.
• Management expresses high confidence in the statistical probability of technical success for regulatory approval based on Phase 3 trial assessments.

Risks

• The initiation, timing, cost, progress, and results of preclinical and clinical studies and research and development programs.
• Ability to advance product candidates into, and successfully complete, clinical studies.
• Timing or likelihood of regulatory filings and approvals.
• Ability to develop, manufacture, and commercialize product candidates and improve the manufacturing process.
• Rate and degree of market acceptance of product candidates.
• Size and growth potential of the markets for product candidates and ability to serve those markets.
• Ability to obtain and maintain intellectual property protection for product candidates.
• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors beyond the company's control.

Future Outlook

MAIA Biotechnology anticipates that the Phase 3 THIO-104 trial results will be consistent with the promising Phase 2 data, potentially leading to ateganosine becoming a new treatment standard for advanced NSCLC patients. The company expects to achieve commercial approval by the U.S. FDA and believes there is a very high probability of technical success for regulatory approval, positioning ateganosine as a major entrant in next-generation cancer treatment with substantial commercial opportunity.

Management Comments

• Our strategy to bring our telomere-targeting treatment to market is proceeding according to plan as we advance our ateganosine program to a Phase 3 trial.
• This larger trial will provide us a robust dataset to support our case for commercial approval by the U.S. FDA.
• With our first patient dosed, we have achieved a key milestone along our path to potential FDA commercial approval.
• We expect to see Phase 3 results consistent with Phase 2 trial data showing median survival of 17.8 months compared to approximately six months of survival from chemotherapy.
• We are confident that ateganosine could become the new treatment standard for patients suffering from this devastating disease.
• We believe that MAIA has positioned itself at the forefront of a new scientific category in oncology.
• Ateganosine remains the only direct telomere-targeting anticancer agent currently in clinical development anywhere—a key distinction in a treatment landscape where most therapeutic advances build upon established mechanisms rather than introduce entirely new ones.
• Statistical assessments of the Phase 3 trial points to a very high probability of technical success for regulatory approval of ateganosine.

Industry Context

MAIA Biotechnology's ateganosine represents a potentially significant advancement in oncology, particularly for advanced non-small cell lung cancer (NSCLC), which remains a challenging global market. Its unique dual mechanism of action, targeting telomeres and activating immune responses, differentiates it from most existing chemotherapies, targeted agents, and immunotherapies that often build upon established mechanisms. As the only direct telomere-targeting anticancer agent currently in clinical development, ateganosine could establish a new therapeutic category, offering a novel approach for patients resistant to current checkpoint inhibitors and chemotherapy.

Comparison to Industry Standards

• Ateganosine's Phase 2 data showed a median overall survival of 17.8 months, significantly exceeding the approximately six months of survival typically observed with chemotherapy in third-line NSCLC patients.
• The observed progression-free survival (PFS) in the THIO-101 trial was 5.6 months, more than double the standard of care PFS of 2.5 months.
• One patient treated with ateganosine in the THIO-101 trial has shown survival of 30 months (912 days) since March 2023, indicating a potentially durable response compared to typical outcomes in this advanced patient population.
• The dual mechanism of action (telomere-targeting plus immune-activation) is presented as unique and not seen in current NSCLC treatments, suggesting a novel approach compared to conventional therapies.

Related Party Transactions

• CEO Dr. Vlad Vitoc and other board members acquired approximately 182,445 shares between November 21 and 28, 2025, in open-market purchases.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress, potential for future regulatory approval, and strong insider confidence, which could lead to increased share value.
• Patients (NSCLC): Potential for a new, more effective third-line treatment option with significantly improved survival and progression-free survival rates compared to current standards.
• Employees: Positive impact from the company's progress and potential for growth, indicating job security and opportunities.
• Regulatory Authorities: The FDA has already granted Fast Track designation, indicating recognition of the drug's potential to address an unmet medical need.

Next Steps

• Continue screening and enrollment for the THIO-104 Phase 3 pivotal trial.
• Generate robust dataset from the Phase 3 trial to support commercial approval by the U.S. FDA.
• Advance ateganosine program towards later-stage development and potential commercialization.
• Obtain regulatory filings and approvals for ateganosine.
• Develop, manufacture, and commercialize ateganosine.
• Improve the manufacturing process for ateganosine.
• Obtain and maintain intellectual property protection for ateganosine.

Key Dates

Recommendation

The initiation of a pivotal Phase 3 trial for a first-in-class drug with highly promising Phase 2 data (significantly outperforming standard of care in OS and PFS) represents a major de-risking event and a critical step towards commercialization. Coupled with strong insider buying by management, FDA Fast Track designation, and a unique mechanism of action, the company demonstrates significant momentum and confidence. The potential to establish a new therapeutic category in a large oncology market like NSCLC suggests substantial upside potential for investors, warranting a 'strong buy' recommendation.

Keywords

MAIA Biotechnology, Ateganosine, THIO, Non-Small Cell Lung Cancer, NSCLC, Phase 3 Clinical Trial, Immuno-oncology, Telomere-targeting, Cancer Therapy, FDA Fast Track, Insider Buying, Biopharmaceutical, Clinical Development, Oncology